Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Calcium Metabolism Disorders

ClinicalTrials.gov lists 532 trials for Calcium Metabolism Disorders or a narrower condition beneath it. Alexion Pharmaceuticals, Inc. has the most among industry and government lead sponsors, with 13.

MeSH D002128 Nutritional and Metabolic Diseases C18
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 24 Phase 1/2 Phase 1/2 15 Phase 2 Phase 2 60 Phase 2/3 Phase 2/3 11 Phase 3 Phase 3 45 Phase 4 Phase 4 57 Not applicable Not applicable 116 Observational Observational 202 Phase 1 Phase 1 24 Phase 1/2 Phase 1/2 15 Phase 2 Phase 2 60 Phase 2/3 Phase 2/3 11 Phase 3 Phase 3 45 Phase 4 Phase 4 57 Not applicable Not applicable 116 Observational Observational 202

Trials per phase

1 more section with rows

14 of the 532 trials are tagged with Calcium Metabolism Disorders itself; the rest are tagged with a narrower condition beneath it.

Get the Calcium Metabolism Disorders report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Calcium Metabolism Disorders trials start? (33)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 2 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 37

1992: 1 trials (Phase 2 1) 1993: 3 trials (Observational 2, Phase 2 1) 1995: 1 trials (Phase 2 1) 1996: 1 trials (Observational 1) 1997: 1 trials (Observational 1) 1998: 1 trials (Not applicable 1) 2000: 1 trials (Phase 2 1) 2001: 3 trials (Observational 1, Phase 3 1, Phase 2 1) 2002: 3 trials (Phase 4 1, Phase 3 1, Phase 2 1) 2003: 4 trials (Observational 2, Not applicable 2) 2004: 11 trials (Observational 2, Not applicable 2, Phase 4 2, Phase 2 2, Phase 1/2 2, Phase 1 1) 2005: 9 trials (Observational 3, Phase 4 3, Phase 3 1, Phase 1/2 1, Phase 1 1) 2006: 18 trials (Observational 6, Not applicable 3, Phase 4 3, Phase 3 2, Phase 2 1, Phase 1/2 2, Phase 1 1) 2007: 9 trials (Not applicable 4, Phase 4 1, Phase 3 1, Phase 1/2 2, Phase 1 1) 2008: 18 trials (Observational 4, Not applicable 3, Phase 4 2, Phase 3 2, Phase 2/3 1, Phase 2 3, Phase 1/2 1, Phase 1 2) 2009: 19 trials (Observational 6, Not applicable 4, Phase 4 2, Phase 3 3, Phase 2 4) 2010: 16 trials (Observational 4, Not applicable 1, Phase 4 3, Phase 3 3, Phase 2/3 3, Phase 2 2) 2011: 22 trials (Observational 10, Not applicable 2, Phase 4 2, Phase 3 3, Phase 2 3, Phase 1/2 1, Phase 1 1) 2012: 25 trials (Observational 10, Not applicable 2, Phase 4 5, Phase 2 6, Phase 1/2 1, Phase 1 1) 2013: 14 trials (Observational 2, Not applicable 3, Phase 4 1, Phase 3 6, Phase 2 2) 2014: 21 trials (Observational 8, Not applicable 5, Phase 4 1, Phase 3 1, Phase 2/3 1, Phase 2 3, Phase 1 2) 2015: 28 trials (Observational 8, Not applicable 8, Phase 4 4, Phase 3 3, Phase 2/3 1, Phase 2 4) 2016: 25 trials (Observational 10, Not applicable 4, Phase 4 3, Phase 3 1, Phase 2 6, Phase 1 1) 2017: 24 trials (Observational 14, Not applicable 4, Phase 4 2, Phase 3 2, Phase 2/3 1, Phase 1 1) 2018: 29 trials (Observational 9, Not applicable 5, Phase 4 6, Phase 3 3, Phase 2/3 1, Phase 2 3, Phase 1 2) 2019: 33 trials (Observational 21, Not applicable 3, Phase 4 4, Phase 3 1, Phase 1/2 1, Phase 1 3) 2020: 28 trials (Observational 15, Not applicable 4, Phase 4 2, Phase 3 1, Phase 2 3, Phase 1/2 1, Phase 1 2) 2021: 37 trials (Observational 14, Not applicable 11, Phase 4 4, Phase 3 6, Phase 2 1, Phase 1 1) 2022: 26 trials (Observational 11, Not applicable 9, Phase 4 2, Phase 3 2, Phase 2/3 1, Phase 2 1) 2023: 17 trials (Observational 5, Not applicable 8, Phase 4 1, Phase 3 1, Phase 2 1, Phase 1 1) 2024: 26 trials (Observational 12, Not applicable 8, Phase 2 3, Phase 1/2 2, Phase 1 1) 2025: 24 trials (Observational 9, Not applicable 9, Phase 4 1, Phase 3 1, Phase 2/3 1, Phase 2 2, Phase 1/2 1)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 24
2025 24
2024 26
2023 17
2022 26
2021 37
2020 28
2019 33
2018 29
2017 24

Showing 10 of 33 earlier years.

Start your 14-day trial Email me all 33 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 29 trials starting in 2026 and about 26 in 2027, the average of the 24 months through September, counted as registered and carried forward, with about 0.7 times the starts already registered for the rest of 2026 added. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 15 percent and ran about 1 percent high against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. The part-way figures are from forecasts that used a multiple fitted only on earlier years. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 29 trials still running at the 2026-10-09 snapshot; registered median of 25 months across 300 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Calcium Metabolism Disorders trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 24
Phase 1/2 15
Phase 2 60
Phase 2/3 11
Phase 3 45
Phase 4 57
Not applicable 116
Observational 202
Expanded access 2

How many Calcium Metabolism Disorders trials are recruiting? (10)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 25
Recruiting 61
Enrolling by invitation 6
Active, not recruiting 24
Available 1

Showing 5 of 10 statuses.

Start your 14-day trial Email me all 10 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Calcium Metabolism Disorders trials? (7)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
Alexion Pharmaceuticals, Inc. 13
Kyowa Kirin Co., Ltd. 12
Amgen 9
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 8
Kyowa Kirin, Inc. 6

Showing 5 of 7 sponsors.

Start your 14-day trial Email me all 7 sponsors as a PDF

Which drugs are being tested for Calcium Metabolism Disorders? (11)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Burosumab 21
Calcitriol 14
Calcium/Vitamin D 14
Cinacalcet 13
Sodium Thiosulfate 11

Showing 5 of 11 drugs.

Start your 14-day trial Email me all 11 drugs as a PDF

Interventions as named in the registry (4)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
CHOLECALCIFEROL 9
Paricalitol 8
theophylline SR 5
Lanthanum Carbonate (Fosrenol, BAY77-1931) Granule 5

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Calcium Metabolism Disorders trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Pneumonia 122 20
Hyperkalaemia 87 8
Sepsis 62 11
Fluid overload 60 9
Cardiac failure congestive 57 7

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Calcium Metabolism Disorders? (7)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Parathyroid and calcium metabolism disorders during pregnancy. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 2013 Yes
Hypercalciuria is a common and important finding in postmenopausal women with osteoporosis. European journal of endocrinology 2003 Yes
Fatty acids, calcium and bone metabolism. Journal of nephrology 2002 Yes
Control of decalcification in orthodontic patients by daily self-administered application of a water-free 0.4 per cent stannous fluoride gel. American journal of orthodontics 1974 Yes
The microvascular pattern of the rotator cuff. The Journal of bone and joint surgery. British volume 1970 Yes

Showing 5 of 7 publications.

Start your 14-day trial Email me all 7 publications as a PDF

Sub-conditions in MeSH (5)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages